Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 5/20 | 0.69 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322896 | 0.78 | LIMK1 (0.68) | LIMK1METKDRHTTTSHR | |
| SCHEMBL735589 | 0.78 | LIMK1 (0.66) | LIMK1KDRHTTTSHRLMNA | |
| SCHEMBL11742 | 0.78 | LIMK1 (0.66) | LIMK1HTTTSHRLMNAMKNK1 | |
| SCHEMBL15883579 | 0.77 | LIMK1 (0.48) | LIMK1METKDRPDE1BKDM4E | |
| SCHEMBL15140475 | 0.74 | LIMK1 (0.42) | LIMK1HTTTSHRLMNAMKNK1 | |
| SCHEMBL2084659 | 0.73 | LMNA (0.52) | LIMK1HTTTSHRLMNAALDH1A1 | |
| SCHEMBL1015876 | 0.73 | SIGMAR1 (0.50) | METKDRDRD2 | |
| SCHEMBL15115915 | 0.72 | HSD17B10 (0.71) | LIMK1LMNAALDH1A1KDM4EGAA | |
| SCHEMBL17296426 | 0.72 | LIMK1 (0.52) | LIMK1HTTTSHRLMNAMKNK1 | |
| Hydrochloric Acid SCHEMBL17296432 | 0.72 | SIGMAR1 (0.49) | METKDRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951878-B2 | Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2005-10-04 | — | — | US | disclosed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | disclosed |
| US-6410586-B1 | ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| US-6262044-B1 | CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING | NOVO NORDISK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-1080095-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999046267-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRA | LIMK1 699/4885MET 460/4885KDR 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.